# Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

> **NCT04121039** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 116 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Advanced Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** POF

## Key facts

- **NCT ID:** NCT04121039
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12
- **Primary completion:** 2021-12
- **Final completion:** 2023-12
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121039, "Study of the Apatinib Combine With POF Versus POF in Gastric Cancer". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT04121039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*